BioCryst Pharmaceuticals (BCRX) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 13.9% versus a gain of 3.5%. Over five years, TARS leads with a +153.2% price change compared with -45.2% for BCRX. Tarsus Pharmaceuticals is the larger company by market cap ($3.38 billion vs $2.12 billion), about 1.6 times the size.
BioCryst Pharmaceuticals converts more of its revenue into profit, with a net margin of 30.2% versus -14.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | TARS |
|---|---|---|
| Share price | $8.29 | $72.22 |
| Market cap | $2.12B | $3.38B |
| 1-day change | -1.31% | -1.89% |
| YTD return | +6.28% | -11.80% |
| 1-year return | +13.87% | +3.54% |
| 5-year return | -45.21% | +153.23% |
| Forward P/E | 8.82 | — |
| EPS (TTM) | $-1.40 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | $451.36M |
| Revenue growth (YoY) | +94.10% | +146.71% |
| Net income (latest FY) | $263.86M | $-66.42M |
| Gross margin | 97.82% | — |
| Operating margin | 38.98% | -15.72% |
| Net margin | 30.16% | -14.72% |
| 52-week high | $11.22 | $91.53 |
| 52-week low | $6.00 | $53.89 |
| Distance from 52-week high | -26.11% | -21.10% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +150.06% | +37.77% |
| Average volume | 4.13M | 894.35K |
| Shares outstanding | 255.54M | 46.79M |
| Employees | 435 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed TARS by 10.3 percentage points over the past year.
- BioCryst Pharmaceuticals is more profitable, keeping 30.2 cents of every revenue dollar as net income versus -14.7 cents for Tarsus Pharmaceuticals.
- Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs +94.10%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
BCRX vs TARS FAQ
Which is bigger, BioCryst Pharmaceuticals or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.38B compared with $2.12B for BioCryst Pharmaceuticals (BCRX).
Which stock has performed better over the past year, BCRX or TARS?
BCRX returned +13.87% over the past 12 months, compared with +3.54% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.